[HTML][HTML] Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
H He, X Qi, H Fu, J Xu, Q Zheng, L Chen, Y Zhang… - Theranostics, 2024 - ncbi.nlm.nih.gov
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
[PDF][PDF] Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
H He, X Qi, H Fu, J Xu, Q Zheng, L Chen, Y Zhang… - researchgate.net
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
[引用][C] Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
H He, X Qi, H Fu, J Xu, Q Zheng, L Chen, Y Zhang… - europepmc.org
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
H He, X Qi, H Fu, J Xu, Q Zheng, L Chen… - …, 2024 - search.proquest.com
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
H He, X Qi, H Fu, J Xu, Q Zheng, L Chen… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
[PDF][PDF] Imaging diagnosis and efficacy monitoring by [89Zr] Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies
H He, X Qi, H Fu, J Xu, Q Zheng, L Chen, Y Zhang… - pdfs.semanticscholar.org
Rationale: Although programmed death-ligand 1 (PD-L1) inhibitors have achieved efficacy
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …
in cancer therapy, their response rate is low. Differences in the prognosis of patients with …